First extensive immune profile of sarcomas shows some likely susceptible to immunotherapy

May 2, 2017, Fred Hutchinson Cancer Research Center

Sarcomas—cancers of the connective tissues like muscles, joints, fat and bone—come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers.

But now a study to be published May 2 in the journal Cancer suggests how both existing and emerging immunotherapy treatments could be successful for sarcomas.

Two sarcoma subtypes—leiomyosarcoma and pleomorphic—showed biological characteristics suggesting they are susceptible to an existing immunotherapy approach known as checkpoint inhibitors. This treatment works by blocking a protein that keeps from attacking cancerous cells.

"Checkpoint inhibitors have transformed the standard of care for melanoma and lung cancer, but it's been tough to make headway in developing immunotherapy strategies for sarcomas," said Dr. Seth Pollack, a clinical researcher at Fred Hutchinson Cancer Research Center and the study's senior author. "Before this study, we had a feeling based on preliminary data that some of the sarcomas would behave very differently based on the , and these findings suggest that we're on the right track."

Sarcomas comprise more than 70 different cancers that can originate anywhere in the body and are usually named after the tissue from which they arise.

In the most extensive sarcoma immune profiling to date, Pollack and his colleagues examined tumor samples from 81 patients with types of sarcoma that comprise 75 percent of the disease: leiomyosarcoma, pleomorphic sarcoma, synovial sarcoma and liposarcoma. The samples came from patients who had agreed to allow researchers to study their tumors for developing new therapies.

The researchers aimed to identify patterns of immune response in these sarcomas to identify promising targets for therapies. They measured:

  • expression of 760 genes, mainly related to immune function;
  • levels of proteins called PD-1 and PD-L1 on T cells that tumors use as an off switch to keep the immune system from attacking cancer cells;
  • the proportion of T cells in tumors, which indicates how successful the immune system is at attacking cancer on its own; and
  • T-cell receptor clonality, which indicates the precision of the T- cell response.

Leiomyosarcoma and pleomorphic sarcomas were the two subtypes that had a greater immune response by nearly all of the measures in the study, which means that they're more visible to the immune system.

"To me, these findings say that there are certain sarcoma subtypes that really lend themselves to the development of checkpoint inhibitor-based strategies," Pollack said. Checkpoint inhibitors are immunotherapies that remove the PD-1 "off switch" and essentially allow the immune system to attack cancer more aggressively.

Meanwhile, synovial sarcoma and liposarcoma had low levels of the immune response markers, suggesting that other immunotherapeutic strategies, such as adoptive T-cell therapies or vaccines, would work better.

"It's too early to change how doctors will treat patients, but these findings are influencing the design of clinical trials in sarcoma," Pollack said.

Other studies have suggested there may be unexpected challenges treating leiomyosarcoma with these therapies and that those patients may benefit from combination approaches with other treatments.

"Our results show that even though other studies have been unclear about whether checkpoint inhibitors work for leiomyosarcoma, that there's still a way to make them work for this subtype and that we need to keep working on it," Pollack said.

Pollack is conducting ongoing clinical trials combining chemotherapies and checkpoint inhibitors:

Ultimately, he hopes to expand treatment options for patients with advanced sarcoma who have an estimated survival of 12 to 18 months.

Sarcomas comprise about 1 percent of all cancers; about 20,000 people a year are diagnosed each year in the United States with one of its many subtypes. Though sarcomas are often called "rare," Pollack said that's a misnomer.

"Indeed there are many rare subtypes of , but added together they have similar incidence compared with other cancers that get more attention such as esophageal , Hodgkin lymphoma and acute myeloid leukemia," he said.

Explore further: Deploying an ancient defense to kill cancer

More information: Seth M. Pollack et al, T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas, Cancer (2017). DOI: 10.1002/cncr.30726

Related Stories

Deploying an ancient defense to kill cancer

April 3, 2017
A recent small trial in 15 cancer patients with advanced soft-tissue sarcomas aimed to find out whether an experimental drug based on a certain bacterial molecule could trigger an immune response to fight cancer.

PI3K/mTOR inhibitors may be effective against some uterine sarcomas

February 23, 2017
The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may ...

Immunotherapy effective against some types of sarcoma

June 6, 2016
An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of ...

Identifying a novel target for cancer immunotherapy

April 12, 2017
Targeting a molecule called B7-H4—which blocks T-cells from destroying tumor cells—could lead to the development of new therapies that boost the immune system's ability to fight cancer, according to a review published ...

CTCA at Western launches immunotherapy clinical trial aimed at soft-tissue cancers

September 18, 2015
Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

PET radiotracer design for monitoring targeted immunotherapy

April 7, 2017
In an article published in the April issue of The Journal of Nuclear Medicine, researchers at Stanford University in California provide a template for assessing new positron emission tomography (PET) radiotracers that can ...

Recommended for you

Study finds melanoma biomarkers predicting checkpoint blocker response

July 18, 2018
Scientists at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood ...

Link found between bitter-taste sensitivity and cancer risk

July 18, 2018
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been ...

Scientists discover a mechanism of drug resistance in breast and ovarian cancer

July 18, 2018
There is a highly sophisticated way to treat some breast and ovarian cancers—a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this ...

Research identifies new breast cancer therapeutic target

July 18, 2018
Research led by Suresh Alahari, Ph.D., Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an ...

Cancer patients may experience delayed skin effects of anti-PD-1 therapy

July 18, 2018
Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay—sometimes even after treatment ...

Early supper associated with lower risk of breast and prostate cancer

July 18, 2018
Having an early supper or leaving an interval of at least two hours before going to bed are both associated with a lower risk of breast and prostate cancer. Specifically, people who take their evening meal before 9 p.m. or ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.